KBI has a large colony of obese NHP models readily available for the needs of research services. 

We routinely evaluate anti-obese efficacy with a wide range of tools including the following techniques:

·  measurements of caloric intake and body mass index (BMI) 

·  quantification of body fat composition with dual energy X-ray absorptiometry (DEXA and iDXA) 

·  measurement of ectopic fat accumulation with magnetic resonance imaging (MRI)  

·  molecular biomarkers (such as adipokine mRNA expression) from fat biopsy in the area of interest

·  profiling of different subtypes of obesity, including central vs subcutaneous obesity, “leptin sensitive” vs “leptin resistant” obesity

·  biopsy of fat tissue for the assessment of adipose browning

Fig 1. Quantification of fat distribution of monkeys by iDEXA at KBI.

Fig 2. Profiling of obese monkeys into leptin sensitive and leptin resistant subtypes at KBI.

Further, we have successfully provided successful services for the evaluation of anti-obese drugs with associated diseases at different stages including:

·  dyslipidemia (including triglyceride, cholesterol, LDL-C, HDL-C and lipoproteins) 

·  pre-diabetes, diabetes and diabetic complications (such as diabetic chronic kidney disease)

·  non-alcoholic fatty liver disease 

·  cardiovascular disease (such as hypertension and heart failure)